BILL ANALYSIS                                                                                                                                                                                                    Ó



                                                                            



           ----------------------------------------------------------------- 
          |SENATE RULES COMMITTEE            |                        SB 809|
          |Office of Senate Floor Analyses   |                              |
          |1020 N Street, Suite 524          |                              |
          |(916) 651-1520         Fax: (916) |                              |
          |327-4478                          |                              |
           ----------------------------------------------------------------- 
           
                                           
                                    THIRD READING


          Bill No:  SB 809
          Author:   DeSaulnier (D) and Steinberg (D), et al.
          Amended:  5/28/13
          Vote:     27 - Urgency

           
           SENATE BUSINESS, PROF. & ECON. DEV. COMM.  :  7-2, 4/15/13
          AYES:  Price, Block, Corbett, Galgiani, Hernandez, Hill, Padilla
          NOES:  Emmerson, Wyland
          NO VOTE RECORDED:  Yee

           SENATE GOVERNANCE & FINANCE COMMITTEE  :  5-2, 5/8/13
          AYES:  Wolk, Beall, DeSaulnier, Hernandez, Liu
          NOES:  Knight, Emmerson

           SENATE APPROPRIATIONS COMMITTEE  :  5-1, 5/23/13
          AYES:  De León, Hill, Lara, Padilla, Steinberg
          NOES:  Gaines
          NO VOTE RECORDED:  Walters


           SUBJECT  :    Controlled substances:  reporting

           SOURCE  :     Attorney General Kamala Harris


           DIGEST  :    This bill charges fees for prescribing health  
          practitioners, dispensers and wholesalers of controlled  
          substances; allows grant and gift moneys for the purposes of  
          upgrading, maintain and enforcing the Controlled Substances  
          Utilization Review and Evaluation System (CURES) Prescription  
          Drug Monitoring Program (PDMP); requires the Medical Board of  
          California (MBC) to periodically develop and disseminate to each  
                                                                CONTINUED





                                                                     SB 809
                                                                     Page  
          2

          licensed physician and surgeon and to each general acute care  
          hospital in California information and educational materials  
          relating to the assessment of a patient's risk of abusing or  
          diverting controlled substances and information relating to  
          CURES; and makes conforming changes.

           Senate Floor Amendments  of 5/28/13 strike the tax provisions;  
          include pharmaceutical manufacturers in the voluntary donation  
          category; and remove the Revenue and Taxation Code section from  
          this bill.

           ANALYSIS  :    Existing law, under the Health and Safety Code,  
          establishes the California Uniform Controlled Substances Act  
          which regulates controlled substances.  

          Existing law, under the Business and Professions Code:

           1. Establishes various Acts which provide for the licensing,  
             certification, and regulation of health practitioners by  
             boards within the Department of Consumer Affairs (DCA).

           2. Provides that a certified nurse-midwife or nurse  
             practitioner may furnish or order drugs or devices, including  
             controlled substances, in accordance with standardized  
             procedures or protocols as specified.  

           3. Establishes the Pharmacy Law which provides for the  
             licensure and regulation of pharmacies, pharmacists and  
             wholesalers of dangerous drugs or devices by the Board of  
             Pharmacy within the DCA.  

           4. Specifies certain requirements regarding the dispensing and  
             furnishing of dangerous drugs and devices, and prohibits a  
             person from furnishing any dangerous drug or device except  
             upon the prescription of a physician, dentist, podiatrist,  
             optometrist, veterinarian or naturopathic doctor.  

           5. Requires the MBC to periodically develop and disseminate  
             information and educational materials regarding various  
             subjects, including pain management techniques, to each  
             licensed physician and surgeon and to each general acute care  
             hospital in California.

          This bill:







                                                                     SB 809
                                                                     Page  
          3


           1. States legislative findings and declarations relating to  
             CURES:

           2. Requires the following health practitioner boards to  
             additionally charge licensees under their supervision that  
             are authorized to prescribe, order, administer, furnish, or  
             dispense controlled substances a fee of up to 1.16% of the  
             renewal fee that the license was subject to as of July 1,  
             2013, assessed annually.  This fee is due and payable at the  
             time the licensee renews his/her license and must be  
             submitted with the licensee's renewal fee, and clarifies that  
             in no case shall the fee exceed the reasonable costs  
             associated with operating and maintaining CURES:  MBC; Dental  
             Board of California (DBC); Board of Pharmacy (BOP);  
             Veterinary Medical Board (VMB); Board of Registered Nursing  
             (BRN); Physician Assistant Committee of the MBC; Osteopathic  
             Medical Board (OMB); Naturopathic Medicine Committee of the  
             OMB; Board of Optometry (CBO); and the Board of Podiatric  
             Medicine (BPM).

           3. Requires the BOP to additionally charge fees for wholesalers  
             and out-of-state wholesalers of dangerous drugs and  
             veterinary food-animal drug retailers of up to 1.16% of the  
             renewal fee that the wholesaler or nonresident wholesaler was  
             subject to as of July 1, 2013, assessed annually.  This fee  
             is due and payable at the time the wholesaler or nonresident  
             wholesaler renews its license and must be submitted with the  
             wholesaler's or nonresident wholesaler's renewal fee.   
             Clarifies that in no case shall this fee exceed the  
             reasonable costs associated with operating and maintaining  
             CURES.

           4. Creates CURES accounts within the Contingent Fund of the  
             MBC, the State Dentistry Fund, the BOP Contingent Fund, the  
             VMB Contingent Fund, the BRN Fund, the Naturopathic Doctor's  
             Fund, the OMB Contingent Fund, the CBO Fund, and the BPM  
             Fund.  Provides that the monies collected from licensing fees  
             for CURES shall be deposited into the CURES account in each  
             fund.  

           5. Provides that monies in the various CURES accounts shall be  
             deposited into the CURES Fund, established within the State  
             Treasury, consisting of all funds made available to DOJ to  







                                                                     SB 809
                                                                     Page  
          4

             operate and maintain CURES.

           6. Requires the MBC to periodically develop and disseminate  
             information and education material regarding assessing a  
             patient's risk of abusing or diverting controlled substances  
             and information relating to CURES to each licensed physician  
             and surgeon and to each general acute care hospital in this  
             state.  Requires MBC to consult with the Department of Health  
             Care Services and DOJ in developing the materials, as  
             specified.

           7. Authorizes DOJ to seek and use grant funds to pay the costs  
             incurred by the operation and maintenance of CURES; and  
             requires DOJ to annually report to the Legislature and make  
             available to the public the amount and sources of funds it  
             receives for support of CURES.  Prohibits grant funds from  
             being appropriated from the MBC, the BOP Contingent Fund, the  
             State Dentistry Fund, the BRN Fund, the Naturopathic Doctor's  
             Fund, the OMB Contingent Fund, the VMB Contingent Fund, the  
             CBO Fund, or the BPM Fund, for the purpose of funding CURES.

           8. Provides that the operation of CURES must comply with all  
             applicable federal and state privacy and security laws and  
             regulations.
              
           9. Allows DOJ to establish policies, procedures, and  
             regulations regarding using, accessing, evaluating, managing,  
             implementing, operating, storing, and securing the  
             information within CURES.
              
           10.Allows DOJ to invite stakeholders to assist, advise, and  
             make recommendations on the establishment of rules and  
             regulations necessary to ensure the proper administration and  
             enforcement of the CURES database.  All prescriber invitees  
             must be licensed, as specified, in active practice in  
             California, and a regular user of CURES.

           11.Requires DOJ, prior to upgrading CURES, to consult with  
             licensed prescribers, as specified, one or more of the  
             identified regulatory boards or commissions, and any other  
             stakeholder identified by DOJ for the purpose of identifying  
             desirable capabilities and upgrades to the CURES PDMP.

           12.Allows DOJ to establish a process to educate authorized  







                                                                     SB 809
                                                                     Page  
          5

             subscribers of CURES on how to access and use CURES.

           13.Requires a licensed health care practitioner eligible to  
             prescribe Schedule II, III or IV controlled substances, or a  
             pharmacist, to submit an application to participate in the  
             CURES PDMP.  Requires DOJ, upon approval of the practitioner  
             or pharmacist subscriber, to release the electronic history  
             of controlled substances dispensed to an individual under  
             his/her care based on data contained in the CURES PDMP.   
             Increases, from 10 to 30 days, the time in which an  
             authorized subscriber must notify the DOJ of any changes to  
             the subscriber account.  Requires DOJ to notify applicants,  
             the Secretary of State, the Secretary of the Senate, the  
             Chief Clerk of the Assembly, and the Legislature when CURES  
             is upgraded and can accommodate all users and include  
             notification on the DOJ Web site, but not before June 1,  
             2015.

           14.Requires DOJ to seek private funds from insurers, health  
             care service plans, and qualified manufacturers for the  
             purpose of supporting CURES; permits specified insurers,  
             health care service plans, and qualified manufacturers to  
             make voluntary contributions to the CURES Fund, which will be  
             nondeductible for state tax purposes; and requires DOJ to  
             make information about funds it receives for support of CURES  
             publicly available.

           15.Defines the following for purposes of this bill:

              A.    "Controlled substance" is a drug, substance or  
                immediate precursor in Schedule II, Schedule III or  
                Schedule IV.

              B.    "Insurer" means an admitted insurer writing health  
                insurance, as defined in Insurance Code (INS) Section 106,  
                and an admitted insurer writing workers' compensation  
                insurance, as defined in INS Section 109.

              C.    "Qualified manufacturer" is a manufacturer of a  
                controlled substance which is not a wholesaler or  
                out-of-state wholesaler of dangerous drugs, a veterinary  
                food-animal drug retailer or a licensee of any of the  
                above-mentioned boards.








                                                                     SB 809
                                                                     Page  
          6

              D.    "Health care service plan" as an entity licensed  
                pursuant to the Knox-Keene Health Care Service Plan Act of  
                1975.

           1. Makes various technical and conforming changes.

           Background
           
           CURES 2.0  .  DOJ is proposing a modernization program for CURES,  
          CURES 2.0 which "seeks to quickly and efficiently serve the  
          state's large medical practitioner community as well as meet the  
          demanding analytical and information requirements of the  
          criminal justice community." 

          DOJ reports in "CURES 2.0:  An Integrated Approach to Preventing  
          Drug Abuse and Diversion" that the current CURES PDMP demands  
          heavy personnel resources for information processing and  
          dissemination.  The system also requires the equivalent of seven  
          Information Technology staff but is slow, frequently freezes and  
          is not capable of accommodating a large influx of new users.   
          The current registration process for the program is time  
          intensive and requires manual data entry and work.  DOJ also  
          notes that the system is currently reactive in nature and has  
          limited reporting and analytical capabilities, as well as  
          underutilized, with only 3.6% of the eligible prescriber and  
          pharmacist licensee field registered as users of CURES.  The  
          current system also has discrepancies between its two data  
          sources that can result in unreliable information.   
            
          A modernized system as outlined by DOJ will result in fewer  
          staff required to maintain the PDMP as well as increased  
          analytical capabilities for regulatory boards and law  
          enforcement to investigate and prevent drug diversion.   
          According to DOJ, CURES 2.0 will provide a streamlined program,  
          system and enrollment process; integration with current major  
          health information systems; timely Patient Activity Reports to  
          prescribers and dispensers; inquiry capabilities to law  
          enforcement and regulatory boards; and, a method of secure data  
          exchange among PDMP users and DOJ.  According to DOJ, the  
          modernized PDMP will enhance information sharing about  
          prescription drug dispensing and prescribing while "promoting  
          legitimate medical practice and quality patient care" and  
          implement two "newly created State of California Regional  
          Investigative Prescription Teams (SCRIPT), a collaborative  







                                                                     SB 809
                                                                     Page  
          7

          effort to significantly diminish the availability and use of  
          illegally obtained prescription drugs through education,  
          training and apprehending those responsible for the distribution  
          and diversion of prescription drugs".  The modernization effort  
          would take approximately 12 to 16 months to complete once  
          funding has been secured and system design efforts begin.  The  
          costs associated with CURES 2.0, as provided by DOJ, are as  
          follows:

          
           ------------------------------------------------------- 
          |PDMP Modernization One-Time Cost - Two Year Period     |
           ------------------------------------------------------- 
          |-------------------------------------------+-----------|
          |Item                                       |Amount     |
          |-------------------------------------------+-----------|
          |Hardware (Server, storage and network)     |$520,541   |
          |-------------------------------------------+-----------|
          |Software (Licensing and maintenance)       |$542,102   |
          |-------------------------------------------+-----------|
          |Design, Development, and Implementation    |$1,032,000 |
          |(Consultant contract based on 4 contract   |           |
          |staff working an estimate of 8600 hours at |           |
          |$120 per hour)                             |           |
          |-------------------------------------------+-----------|
          |Estimated One-Time Cost                    |$2,090,643 |
          |                                           |           |
           ------------------------------------------------------- 
          
          The $2,090,643 cost above would be for modernizing the PDMP to  
          meet the needs of medical practitioners and law enforcement. 

          
           ------------------------------------------------------- 
          | Transitional System Cost - Two Year Period            |
           ------------------------------------------------------- 
          |-------------------------------------------+-----------|
          |System                                     |Amount     |
          |-------------------------------------------+-----------|
          |  Information Technology Staff (7)        |$1,300,000 |
          |-------------------------------------------+-----------|
          |  Electronic Data Service (to obtain      |$260,000   |
          |  pharmacy data)                           |           |
          |-------------------------------------------+-----------|







                                                                     SB 809
                                                                     Page  
          8

          |  Maintenance (hardware, software)        |$270,000   |
          |-------------------------------------------+-----------|
          |Estimated Cost to Operate System During    |$1,830,000 |
          |Two Year Period:                           |           |
           ------------------------------------------------------- 
          
          The $1,830,000 cost identified above would be necessary to  
          operate and maintain the current PDMP until data could be  
          migrated to the modernized PDMP.  

          
           ------------------------------------------------------- 
          |CURES 2.0 Program and System Cost Ongoing - Year Three |
          |                                                       |
           ------------------------------------------------------- 
          |-------------------------------------------+-----------|
          |Program                                    |Amount     |
          |-------------------------------------------+-----------|
          |  CURES Support Staff (9)                 |$ 776,554  |
          |-------------------------------------------+-----------|
          |  Travel/Training (system registration    |$15,000    |
          |  outreach; training system users;         |           |
          |  stakeholder meetings)                    |           |
          |-------------------------------------------+-----------|
          |  System                                   |           |
          |-------------------------------------------+-----------|
          |  Information Technology Staff (5)        |$500,000   |
          |-------------------------------------------+-----------|
          |  Electronic Data Service (to obtain      |$130,000   |
          |  pharmacy data)                           |           |
          |-------------------------------------------+-----------|
          |  Maintenance (hardware, software)        |$200,000   |
          |-------------------------------------------+-----------|
          |Total:                                     |$1,621,554 |
          |                                           |           |
           ------------------------------------------------------- 
          
          The $1,621,554 cost identified above would be for staffing,  
          operating, and maintaining the modernized PDMP on a yearly  
          basis.  This cost would include any necessary hardware and/or  
          software upgrades.  This bill seeks to fund this effort through  
          the proposed 1.16% increase in licensing fees for prescribers,  
          pharmacists and wholesalers.  As proposed, this fee increase  
          would result in approximately:  







                                                                     SB 809
                                                                     Page  
          9


             $9 increase on the current $808 licensing fee for physicians  
             and surgeons.

             $4 increase on the current $365 licensing fee for dentists.

             $2 increase on the current $150 licensing fee for  
             pharmacists.

             $7 increase on the current $600 licensing fee for  
             wholesalers, including out-of-state wholesalers.

             $5 increase on the current $405 licensing fee for veterinary  
             retailers.

             $3 increase on the current $290 licensing fee for  
             veterinarians.

             $2 increase on the current $140 licensing fee for nurse  
             midwives.

             $2 increase on the current $140 licensing fee for nurse  
             practitioners.

             $3 increase on the current $300 licensing fee for physician  
             assistants.

             $5 increase on the current $400 licensing fee for  
             osteopathic physicians and surgeons.

             $5 increase on the current $425 licensing fee for  
             optometrists.

             $10 increase on the current $900 licensing fee for permanent  
             doctors of podiatric medicine.
          
           ------------------------------------------------------- 
          |Statewide SCRIPT Team                                  |
           ------------------------------------------------------- 
          |-------------------------------------------+----------|
          |Program  - SCRIPT Team (19)                |$         |
          |                                           |    4,307,343|
          |-------------------------------------------+----------|
          |Total:                                     |$         |







                                                                     SB 809
                                                                     Page  
          10

          |                                           |4,307,343 |
          |                                           |          |
           ------------------------------------------------------ 
          
          The $4,307,343 cost identified above would fund two SCRIPT, with  
          one team located in Northern California and one in Southern  
          California.  These SCRIPT teams would be tasked with  
          investigating prescription drug diversion, coordinating cases  
          with the MBC, as well as the coordination of state, federal and  
          local law enforcement efforts.   These teams would provide  
          statewide jurisdiction for cases involving organized diversion  
          and the misuse of scheduled medication.  

           NOTE:  For detailed information relating to the five Schedules  
                 of controlled substances, prescription drug  
                 abuse/deaths/monitoring, and CURES, refer to the Senate  
                 Business, Professions and Economic Development  
                 Committee's analysis.

           Comments
           
          According to the Senate Governance and Finance Committee, the  
          funding for the CURES PDMP is set to expire on July 1, 2013.   
          This bill attempts to fully fund CURES PDMP before the  
          expiration date.

           FISCAL EFFECT  :    Appropriation:  No   Fiscal Com.:  Yes    
          Local:  No

          According to the Senate Appropriations Committee:

             Potential one-time costs in the hundreds of thousands for  
             various professional regulating boards within DCA to revise  
             regulations to increase existing fees (various special  
             funds).

             Ongoing revenue increase of $800,000 from increases in  
             various professional licensing fees (various special funds).

             One-time costs of about $4.6 million over two years to  
             continue operation of the existing CURES system and develop  
             an upgraded system by DOJ (CURES Fund).

             Ongoing costs of about $5.2 million per year to maintain the  







                                                                     SB 809
                                                                     Page  
          11

             upgraded CURES and to support enforcement activities by DOJ  
             (CURES Fund).

           SUPPORT  :   (Verified  5/29/13)

          Attorney General Kamala Harris (source) 
          ALPHA Fund
          American Cancer Society Cancer Action Network 
          American Medical Association
          Association of California Healthcare Districts
          Association of California Insurance Companies
          Behind the Orange Curtain, the Documentary
          California Association for Nurse Practitioners 
          California Association of Joint Powers Authority
          California Chapter of the American College of Emergency  
          Physicians 
          California Coalition on Workers' Compensation
          California Department of Insurance
          California Joint Powers Insurance Authority
                                                                           California Labor Federation
          California Medical Association 
          California Narcotic Officers Association 
          California Pharmacists Association
          California Police Chiefs Association
          California Professional Association of Specialty Contractors
          California Retailers Association
          California Self-Insurers Association
          California Society of Health-System Pharmacists 
          California State Association of Counties
          California State Board of Pharmacy
          California State Sheriffs' Association
          City and County of San Francisco
          County Alcohol and Drug Program Administrators Association of  
          California 
          CSAC Excess Insurance Authority
          Deputy Sheriffs' Association of San Diego County
          Employers Group
          Gallagher Bassett Services, Inc.
          Golden Oak Cooperative Corporation
          Grimmway Farms
          Health Officers Association of California
          Healthcare Distribution Management Association
          Independent Insurance Agents and Brokers of California
          Metro Risk Management







                                                                     SB 809
                                                                     Page  
          12

          Michael Sullivan & Associates
          National Association of Chain Drug Stores 
          National Coalition Against Prescription Drug Abuse
          Nordstrom
          Safeway
          Schools Insurance Authority
          Schools Insurance Group
          Sedgwick Claims Management Services
          Shaw, Jacobsmeyer, Crain, and Claffey
          South Orange County Coalition
          Troy and Alana Pack Foundation
          University of California 
          Western Occupational & Environmental Medical Association
          Western Propane Gas Association

           OPPOSITION  :    (Verified  5/29/13)

          BayBio
          California Healthcare Institute
          Generic Pharmaceutical Association

           ARGUMENTS IN SUPPORT  :    According to the author's office, the  
          automated PDMP within the CURES program is a valuable  
          investigative, preventative, and educational tool for law  
          enforcement, regulatory boards, and health care providers, but  
          recent budget cuts to the Attorney General's Division of Law  
          Enforcement have resulted in insufficient funding to support the  
          CURES PDMP.  The author's office states that the PDMP is  
          necessary to ensure health care professionals have the necessary  
          data to make informed treatment decisions and to allow law  
          enforcement to investigate prescription drug diversion.  Without  
          a dedicated funding source, the CURES PDMP is not sustainable  
          and will be suspended July 1, 2013.  To keep the program going  
          and increase its effectiveness, this bill establishes funds to  
          upgrade the system to be fully modernized and provides dedicated  
          ongoing funding to ensure the program is sustainable.

          The bill's sponsor, California Attorney General Kamala Harris  
          (AG), notes that without the funding this bill provides, the AG  
          will be forced to disband the CURES program later this year,  
          making California one of only two states in the nation without a  
          PDMP and that closing the CURES program would "exacerbate a  
          prescription drug diversion problem that is already the fastest  
          growing drug problem in the United States."







                                                                     SB 809
                                                                     Page  
          13


           ARGUMENTS IN OPPOSITION  :    No letters on file.


          MW:k  5/29/13   Senate Floor Analyses 

                           SUPPORT/OPPOSITION:  SEE ABOVE

                                   ****  END  ****